Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.
Revenue was up $200 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.0 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Lineage Cell Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.04 | -0.04 | -0.04 | -0.04 |
| EPS Actual | -0.04 | -0.03 | -0.03 | -0.03 |
| Revenue Estimate | 2.59M | 2.20M | 2.01M | 2.57M |
| Revenue Actual | 1.25M | 3.23M | 2.39M | 1.90M |
To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
